Literature DB >> 6458323

Structure of fragment E species from human cross-linked fibrin.

S A Olexa, A Z Budzynski, R F Doolittle, B A Cottrell, T C Greene.   

Abstract

Fragments E1, E2, and E3 are plasmic derivatives of fibrin encompassing the NH2-terminal region of the molecule. The first two species, but not the third, can bind to fragment DD, forming a (DD)E complex, and therefore probably contain binding sites involved in the polymerization of fibrin. For localization of these sites the structure of the fragments was determined by establishing the NH2- and COOH-terminal boundaries of the molecules and using the published amino acid sequence of fibrinogen. Fragment E1 encompasses Gly-alpha 17 to Lys-alpha 78, Gly-beta 15 to Lys-beta 122, and Tyr-gamma 1 to Lys-gamma 62, this representing the intact NH2-terminal region of fibrin. Fragment E2 is an asymmetric molecule which is lacking the sequence of Gly-beta 15 to Lys-beta 53 in one beta-chain remnant. This fragment E2 also lost Lys-beta 122 from the COOH terminal of the beta chain as compared with fragment E1. These cleavages did not affect the ability of fragment E2 to bind to fragment DD. Fragment E3 was heterogeneous, the main species encompassing Val-alpha 20 to Lys-alpha 78, Lys-beta 54 to Leu-beta 120, and Tyr-gamma 1 to Lys-gamma 53. Thus, the loss of the binding function involved in the formation of fibrin clot was associated with the removal of small fragments from all three polypeptide chains: alpha 17-19 (Gly-Pro-Arg), beta 15-53 from the remaining half of the molecule, beta 121 (Leu), and gamma 54-58 (Thr-Ser-Glu-Val-Lys).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6458323     DOI: 10.1021/bi00524a035

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  13 in total

1.  Crystal structure of the central region of bovine fibrinogen (E5 fragment) at 1.4-A resolution.

Authors:  J Madrazo; J H Brown; S Litvinovich; R Dominguez; S Yakovlev; L Medved; C Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-09       Impact factor: 11.205

2.  Generation of forms of fragment E with differing thrombin-binding properties during digestion of fibrinogen by plasmin.

Authors:  C A Goodwin; V V Kakkar; M F Scully
Journal:  Biochem J       Date:  1992-02-01       Impact factor: 3.857

3.  Free-radical oxidation of fibrinogen fragments D and E.

Authors:  M A Rozenfeld; V B Leonova; A N Shegolihin; S D Razumovskii; M L Konstantinova; A V Bychkova; A L Kovarskii
Journal:  Dokl Biochem Biophys       Date:  2010-08-17       Impact factor: 0.788

Review 4.  Novel aspects of fibrin(ogen) fragments during inflammation.

Authors:  Carla Jennewein; Nguyen Tran; Patrick Paulus; Peter Ellinghaus; Johannes Andreas Eble; Kai Zacharowski
Journal:  Mol Med       Date:  2011-01-04       Impact factor: 6.354

Review 5.  Fibrin(ogen) and its fragments in the pathophysiology and treatment of myocardial infarction.

Authors:  Kai Zacharowski; Paula Zacharowski; Sonja Reingruber; Peter Petzelbauer
Journal:  J Mol Med (Berl)       Date:  2006-05-06       Impact factor: 4.599

6.  Effect of fibrinogen, fibrin, and fibrin degradation products on transendothelial migration of leukocytes.

Authors:  Sergiy Yakovlev; Leonid Medved
Journal:  Thromb Res       Date:  2017-11-21       Impact factor: 3.944

7.  Molecular basis for fibrinogen Dusart (A alpha 554 Arg-->Cys) and its association with abnormal fibrin polymerization and thrombophilia.

Authors:  J Koopman; F Haverkate; J Grimbergen; S T Lord; M W Mosesson; J P DiOrio; K S Siebenlist; C Legrand; J Soria; C Soria
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

8.  Specific uptake of radioiodinated fragment E1 by venous thrombi in pigs.

Authors:  L C Knight; S A Olexa; L S Malmud; A Z Budzynski
Journal:  J Clin Invest       Date:  1983-12       Impact factor: 14.808

9.  Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.

Authors:  J I Weitz; B Leslie; J Ginsberg
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

10.  "Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules.

Authors:  M Matsuda; M Baba; K Morimoto; C Nakamikawa
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.